Lonza 1H13: Lonza reported growth of approximately 10%, with Pharma & Biotech segment sales of CHF 609 million.   Comments: In the Manufacturing segment, several segments experienced growth, including microbial and mammalian technology offerings, and integrated ADC offerings, as well as new contracts for small molecule products. Custom Development growth was attributed to the mammalian business and expanded microbial capabilities, as well as cell therapy process development services. Biosci...